Loading stock data…
ENTA
$14.35+0.46 (+3.31%)
Market ClosedLast close May 1
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enanta Pharmaceuticals, Inc. in the Healthcare sector is trading at $14.35. The stock is currently 16% below its 52-week high of $17.15, remaining 21.4% above its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why ENTA maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.35
Potential Upside
5%
Whystock Fair Value$15.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$400.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-56.51%
Volume
Today's trading volume
145,560
Recent News
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
Enanta Pharmaceuticals (NASDAQ:ENTA) used a presentation at the Citizens Life Sciences Conference to outline its evolving pipeline strategy, highlighting late-stage ambitions in respiratory syncytial virus (RSV) and a growing immunology and inflammation (I&I) portfolio built around small-molecul
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +21.50% and +19.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
WATERTOWN, Mass. AP) — Enanta Pharmaceuticals Inc. ENTA) on Monday reported a loss of $11.9 million in its fiscal first quarter.
JPM26: Enanta outlines strategy to lead in RSV therapeutics
Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.